ResMed Corporation (RMD) - התחייבויות לטווח ארוך להון

ResMed Inc. (RMD) production facilities in the US, Singapore, and Australia ensure business resilience through stable demand for respiratory therapy devices. The company is expanding its profile by implementing cloud services for remote patient monitoring, which minimizes the risk of price erosion for core devices. Serving as a valuation tool, this chart of long-term liabilities to equity at 0.08 confirms the brand's dominance and high customer loyalty to the AirView ecosystem.

ResMed Inc. (RMD) maintains its leadership in apnea therapy, yet the expansion of GLP-1 drugs and pressure from Medicare tariffs create risks for cash flow stability. The long-term debt-to-equity ratio measures the proportion of borrowed financing exceeding one year, allowing investors to assess financial stability and debt load via this chart of long-term debt to equity.